Human immunodeficiency virus type 1 protease inhibitors

Archives of Internal Medicine

Volumn 157, Issue 9, 1997, Pages 951-959

  McDonald, Cheryl K ^a   Kuritzkes, Daniel R ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL DISCOMFORT; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DIARRHEA; DRUG DESIGN; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSOMNIA; LYMPHOCYTE COUNT; MUSCLE WEAKNESS; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; VOMITING;

EID: 0030993833     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.9.951     Document Type: Review

References (86)

1. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987;317:192-197.
2. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science. 1989;243:1731-1734.
3. Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses. 1992;8:153-164.
4. Loeb DD, Hutchison CA, Edgell MH, Farmerie WG, Swanstrom R. Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases. J Virol. 1989;63:111-121.
5. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A. 1988;85:4686-4690.
6. Peng C, Ho BK, Chang TW, Chang NT. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol. 1989;63:2550-2556.
7. Gottlinger HG, Sodroski JG, Haseltine WA. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1989;86:5781-5785.
8. Navia MA, Fitzgerald PMD, McKeever BM, et al. Three-dimensional structure of aspartyl protease from HIV-1. Nature. 1989;337:615-620.
9. Wlodawer A, Miller M, Jaskolski M, et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science. 1989; 245:616-621.
10. Robins T, Plattner J. HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J Acquir Immune Defic Syndr. 1993;6:162-170.
11. Dreyer GB, Metcalf BW, Tomaszec TA, et al. Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc Natl Acad Sci U S A. 1989; 86:9752-9756.
12. Meek TD, Lambert DM, Dreyer GB, et al. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature. 1990;343:90-92.
13. Ashorn P, McQuade TJ, Thaisrivongs S, Tomasselli AG, Tarpley WG, Moss B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci U S A. 1990;87: 7472-7476.
14. McQuade TJ, Tomasselli AG, Liu L, et al. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science. 1990;247:454-456.
15. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990;248:358-361.
16. Kageyama S, Anderson BD, Hoesterey BL, et al. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob Agents Chemother. 1994;38:1107-1111.
17. Bilello JA, Bilello PA, Prichard M, Robins T, Drusano GL. Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein. J Infect Dis. 1995;171:546-551.
18. 2 symmetric inhibitor complexed to HIV-1 protease. Science. 1990;249:527-533.
19. Alteri E, Bold G, Cozens R, et al. CGP 53437, an orally bioavailable inhibitor of HIV type 1 protease with potent antiviral activity. Antimicrob Agents Chemother. 1993;37:2087-2092.
20. Vacca JP, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A. 1994;91:4096-4100.
21. Bechtold CM, Patick AK, Alam M, et al. Antiviral properties of aminodiol inhibitors against HIV and protease. Antimicrob Agents Chemother. 1995; 39:374-379.
22. Lam PYS, Jakhav PK, Eyermann CJ, et al. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science. 1994;263:380-384.
23. Reich SH, Melnick M, Davies JF, et al. Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of HIV protease. Proc Natl Acad Sci U S A. 1995;92:3298-3302.
24. Kempf DJ, Marsh KC, Denissen DF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A. 1995;92:2484-2488.
25. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, Mills JS. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus proteinase. Antiviral Res. 1991;16:295-305.
26. Perno CF, Bergamini A, Pesce CD, et al. Inhibition of the protease of HIV blocks replication and infectivity of the virus in chronically infected macrophages. J Infect Dis. 1993;168:1148-1156.
27. Perno CF, Aquaro S, Rosenwirth B, et al. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J Leukoc Biol. 1994;56:381-386.
28. 2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother. 1992;36:926-933.
29. Johnson VA, Merrill DP, Chou TC, Hirsch MS. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis. 1992;166:1143-1146.
30. Lambert DM, Bartus H, Fernandez AV, et al. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection. Antiviral Res. 1993;21:327-342.
31. Zhang XQ, Livingston D, Tung R, Schooley RT. Synergistic inhibition of HIV-1 replication in vitro by protease inhibitors and zidovudine. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy; October 4-7, 1994; Orlando, Fla. Abstract I-74.
32. Pagano PJ, Chong KT. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha. J Infect Dis. 1995;171:61-67.
33. Erickson-Viitanen S, Klabe RM, Cawood PG, O'Neal P, Meek JL. Potency and selectivity of inhibition of HIV protease by a small nonpeptide cyclic urea, DMP 323. Antimicrob Agents Chemother. 1994; 38:1628-1634.
34. 2 symmetry-based HIV protease inhibitor. Antimicrob Agents Chemother. 1995; 39:1559-1564.
35. Sommadossi JP, Schinazi RF, McMillan A, Xie A, Bryant M. A human serum glycoprotein profoundly affects antiviral activity of the protease inhibitor SC-52151 by decreasing its cellular uptake. In: Program and abstracts of the First National Conference on Human Retroviruses and Related Infections; December 12-16, 1993; Washington, DC. Abstract LB4.
36. Muirhead GJ, Shaw T, Williams PEO, Madigan MJ, Mitchell AM, Houston AC. Pharmacokinetics of the HIV-proteinase inhibitor, Ro 318959, after single and multiple oral doses in healthy volunteers. Br J Clin Pharmacol. 1992;34(suppl) :170P-171P.
37. Shaw TM, Williams PE, Muirhead GJ, Harris S, Watson N, Nimmo W. Effect of timing of food and gastric pH on exposure to Ro31-8959, HIV proteinase inhibitor in healthy subjects. In: Program and abstracts of the Ninth International Conference on AIDS; June 7-11, 1993; Berlin, Germany. Abstract PO-B30-2199.
38. + T-cell counts in HIV-infected patients. Ann Intern Med. 1996;124:1039-1050.
39. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med. 1995;328:1528-1533.
40. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995;328:1534-1539.
41. Teppler H, Pomerantz R, Bjornsson T, et al. Pharmacokinetics and tolerability studies of L-735,524, a new HIV protease inhibitor. In: Program and abstracts of the First National Conference on Human Retroviruses and Related Infections; December 12-16, 1993; Washington, DC. Abstract L8.
42. Steigbigel RT, Berry P, Mellors J, et al. Efficacy and safety of the HIV protease inhibitor indinavir sulfate (MK 639) at escalating dose. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract 146.
43. Quart BD, Chapman SK, Peterkin J, Webber S, Oliver S. Phase I safety, tolerance, pharmacokinetics and food effect studies of A61343: a novel protease inhibitor. In: Program and abstracts of the Second National Conference on Human Retroviruses and Related Infections; January 29-February 2, 1995; Washington, DC. Abstract LB3.
44. Kempf D, Marsh K, Denissen J, et al. Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract 143.
45. Cameron W, Sun E, Markowitz M, et al. Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data. In: Program and abstracts of the 11th International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Th.B.934.
46. Webber S, Shetty B, Wu E, Zorbas M. In vitro and in vivo metabolism and cytochrome P450 induction studies with the HIV-1 protease inhibitor, Viracept (AG 1343). In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract 144.
47. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet. 1995;345:952-955.
48. Collier AC, Coombs RW, Timpone J, et al. Comparative study of Ro 31-8959 and zidovudine (ZDV) vs ZDV and zalcitabine (DDC) vs Ro 31-8959, ZDV, and DDC. In: Program and abstracts of the 10th International Conference on AIDS; August 7-12, 1994; Yokohama, Japan. Abstract 058B.
49. 3. In: Program and abstracts of the Second National Conference on Human Retroviruses and Related Infections; January 29-February 2, 1995; Washington, DC. Abstract 183.
50. Deutsch P, Teppler H, Squires K, et al. Antiviral activity of L-735,524, an HIV protease inhibitor, in infected patients. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 4-7, 1994; Orlando, Fla. Abstract I-59.
51. Massari F, Conant M, Mellors J, et al. A phase II open label, randomized study of the triple combination of indinavir, zidovudine (ZDV) and didanosine (DDI) versus indinavir alone and ZDV/ DDI in antiretroviral naive patients. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract 200.
52. Moyle GJ, Youle M, Higgs C, et al. Extended follow-up and safety and activity of Agouron's HIV proteinase inhibitor AG1343 (Viracept) in virological responders from the UK phase I/II dose finding study. In: Program and abstracts of the 11th International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Mo.B.173.
53. Gathe J Jr, Burkhardt B, Hawley P, Conant M, Peterkin J, Chapman S. A randomized phase II study of Viracept, a novel HIV protease inhibitor, used in combination with stavudine (d4T) vs stavudine (d4T) alone. In: Program and abstracts of the 11th International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Mo.B.413.
54. Mellors JW, McMahon DK, Chodakewitz JA, Schleif WA, Emini EA, Condra IH. Correlation between genotypic evidence of HIV-1 resistance to the protease inhibitor MK-639 and loss of antiretroviral effect in treated patients. In: Program and abstracts of the Fourth International Workshop on HIV Drug Resistance; July 6-9, 1995; Sardinia, Italy. Abstract 71.
55. Eastman PS, Kelso R, Boyer E, et al. Loss of suppression of viral replication by ritonavir (ABT-538) is quantitatively associated with the acquisition of genotypic mutations at codon 82 of the HIV-1 protease gene. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract 201.
56. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2: 760-766.
57. Craig IC, Duncan IB, Roberts NA, Whittaker L. Ro 31-8959, an inhibitor of HIV proteinase, appears relatively refractory to the generation of virus mutants with reduced sensitivity. In: Program and abstracts of the Ninth International Conference on AIDS; June 7-11, 1993; Berlin, Germany. Abstract PO-A26-0649.
58. Mous J, Brun-Vezinet F, Duncan IB, Hanggi M, Jacobsen H, Vella S. Characterization of in vivo selected HIV-1 variants with reduced sensitivity to proteinase inhibitor saquinavir. In: Program and abstracts of the 10th International Conference on AIDS; August 7-12, 1994; Yokohama, Japan. Abstract 515B.
59. Jacobsen H, Yasargil IC, Winslow DL, et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology. 1995; 206:527-534.
60. Kaplan AH, Michael SF, Wehbie RS, et al. Selection of multiple HIV type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci U S A. 1994;91:5597-5601.
61. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED. Cross-resistance analysis of HIV type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother. 1995;39:1704-1710.
62. Markowitz M, Mo H, Kempt DJ, et al. Selection and analysis of HIV type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol. 1995;69:701-706.
63. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569-571.
64. Duncan IB, Jacobsen H, Owen S, Roberts NA. Reduced HIV sensitivity during treatment with the proteinase inhibitor saquinavir. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract 155.
65. Schapiro JM, Winters M, Merigan TC. Mutational analysis of the saquinavir high dose monotherapy study. In: Program and abstracts of the Fourth International Workshop on HIV Drug Resistance; July 6-9, 1995; Sardinia, Italy. Abstract 73.
66. Condra JH, Schleif WA, Blahy OM, et al. In vivo evolution of resistance to the HIV-1 protease inhibitor indinavir. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract 145.
67. Delfraissy JF, Sereni D, Brun-Vezinet F, et al. A phase I-II dose ranging study of the safety and activity of Ro 31-8959 (HIV-proteinase inhibitor) in previously zidovudine (ZDV) treated HIV-infected individuals. In: Program and abstracts of the Ninth International Conference on AIDS; June 7-11, 1993; Berlin, Germany. Abstract WS-B26-3.
68. Vella S. HIV therapy advances: update on a proteinase inhibitor. AIDS. 1994;8(suppl):S25-S29.
69. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996;334:1011-1017.
70. Salgo M, Beattie D, Bragman K, et al. Saquinavir vs Hivid vs combination as treatment for advanced HIV infection in patients discontinuing/ unable to take Retrovir. In: Program and abstracts of the 11th International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Mo.B.410.
71. + cells per cubic millimeter. N Engl J Med. 1995;333:1662-1669.
72. Mathez D, de Truchis P, Gorin I, et al. Ritonavir, AZT, DDC, as a triple combination in AIDS patients. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract 285.
73. Cameron B, Heath-Chiozzi M, Kravcik S, Mills R, Potthoff A, Henry D. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract LB-6a.
74. Steigbigel R, Berry P, Teppler H, et al. Extended follow-up of patients in a study of indinavir at 800 mg q8h (2.4 g/d), 100 mg q8h (3.0 g/d), and 800 mg q6h (3.2 g/d). In: Program and abstracts of the 11th International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Mo.B.412.
75. 3. In: Program and abstracts of the 11th International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract LB.B.6017.
76. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC). In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington, DC. Abstract LB-7.
77. Gulick RM, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV), and lamivudine (3TC). In: Program and abstracts of the 11th International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Th.B.931.
78. Conant M, Markowitz M, Hurley A, Ho D, Peterkin J, Chapman S. A randomized phase II dose range-finding study of the HIV protease inhibitor Viracept as monotherapy in HIV positive patients. In: Program and abstracts of the 11th International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Tu.B.2129.
79. Powderly W, Sension M, Conant M, Stein A, Clendeninn N. The efficacy of Viracept in pivotal phase II/III double-blind, randomized, controlled trials as monotherapy and in combination with d4T or AZT/3TC. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 370.
80. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med. 1996;2:625-629.
81. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
82. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-122.
83. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271: 1582-1586.
84. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. JAMA. 1996;276:146-154.
85. + cells. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract LB3.
86. Marsh K, McDonald E, Sham H, Dempf D, Norbeck D. Enhancement of ABT-378 pharmacokinetics when administered in combination with ritonavir. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1996; Washington, DC. Abstract 210.